Literature DB >> 15750842

[Therapy of organ failure in primary extracardiac diseases].

S Reith1, K Werdan.   

Abstract

There are a number of primary extracardiac circulatory disorders leading to organ dysfunction, multi-organ dysfunction syndrome and finally to multi-organ-failure. The origin of this hemodynamic disturbances are potentially different forms of circulatory shock (septic, hypovolemic, anaphylactic or neurogenic shock) and the systemic inflammatory reaction syndrome (SIRS). The primary aim of therapy is the removal of the underlying causes and the restoration of adequate tissue perfusion by using fluids, vasopressors and inotropics. The supportive treatment of the individual organ dysfunction is - at present - unequally efficient.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15750842     DOI: 10.1007/s00108-005-1352-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  25 in total

Review 1.  The pathogenesis of vasodilatory shock.

Authors:  D W Landry; J A Oliver
Journal:  N Engl J Med       Date:  2001-08-23       Impact factor: 91.245

Review 2.  Current controversies in shock and resuscitation.

Authors:  M Orlinsky; W Shoemaker; E D Reis; M D Kerstein
Journal:  Surg Clin North Am       Date:  2001-12       Impact factor: 2.741

Review 3.  [Autonomic dysfunction in critically ill patients].

Authors:  H Schmidt; U Müller-Werdan
Journal:  Internist (Berl)       Date:  2002-09       Impact factor: 0.743

Review 4.  Corticosteroids in sepsis: from bench to bedside?

Authors:  Djillali Annane; Jean-Marc Cavaillon
Journal:  Shock       Date:  2003-09       Impact factor: 3.454

5.  Pro/Con debate of activated protein C in severe sepsis.

Authors:  J C A Joore; H J van Leeuwen; J Meulenbelt; T J M Tobé; J W Fijen; J W Figen
Journal:  Crit Care Med       Date:  2003-08       Impact factor: 7.598

6.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study.

Authors:  Richard Moreau; Francois Durand; Thierry Poynard; Christian Duhamel; Jean-Paul Cervoni; Philippe Ichaï; Armand Abergel; Chantal Halimi; Mathieu Pauwels; Jean-Pierre Bronowicki; Emile Giostra; Cathy Fleurot; Danielle Gurnot; Olivier Nouel; Philippe Renard; Michel Rivoal; Pierre Blanc; Dimitri Coumaros; Sylvie Ducloux; Stephane Levy; Alexandre Pariente; Jean-Marc Perarnau; Jean Roche; Myriam Scribe-Outtas; Dominique Valla; Brigitte Bernard; Didier Samuel; Joël Butel; Antoine Hadengue; Andrzej Platek; Didier Lebrec; Jean-Francois Cadranel
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

7.  Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis.

Authors:  M Mohr; L Englisch; A Roth; H Burchardi; S Zielmann
Journal:  Intensive Care Med       Date:  1997-11       Impact factor: 17.440

8.  Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study.

Authors:  B Levy; P E Bollaert; C Charpentier; L Nace; G Audibert; P Bauer; P Nabet; A Larcan
Journal:  Intensive Care Med       Date:  1997-03       Impact factor: 17.440

9.  Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis.

Authors:  Derek C Angus; Walter T Linde-Zwirble; Gilles Clermont; Daniel E Ball; Bruce R Basson; E Wesley Ely; Pierre-Francois Laterre; Jean-Louis Vincent; Gordon Bernard; Ben van Hout
Journal:  Crit Care Med       Date:  2003-01       Impact factor: 7.598

10.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock.

Authors:  Djillali Annane; Véronique Sébille; Claire Charpentier; Pierre-Edouard Bollaert; Bruno François; Jean-Michel Korach; Gilles Capellier; Yves Cohen; Elie Azoulay; Gilles Troché; Philippe Chaumet-Riffaud; Philippe Chaumet-Riffaut; Eric Bellissant
Journal:  JAMA       Date:  2002-08-21       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.